Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Symbol
- NUVB
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.11B
- 52 week range
- 2.99 - 9.75
Valuation
- Share price
- $5.71 (close of 2026-09-23)
- P/E (TTM)
- -14.19x
- Price to book
- 8.33x
- Price to free cash flow
- -17.54x
- Enterprise value
- $2.11B
- Book value per share
- $0.73
Price performance
| Period | Change |
|---|
| 1 day | -5.93% |
| 5 days | -1.55% |
| 1 month | -17.60% |
| 3 months | -5.46% |
| 6 months | +31.26% |
| Year to date | -36.27% |
| 1 year | +77.33% |
| 3 years | +329.32% |
| 5 years | -39.90% |
| All time | -41.13% |
Profitability and growth
- Return on equity
- -66.93%
- Return on invested capital
- -107.08%
- Return on assets
- -34.40%
- Return on capital employed
- -41.57%
- Gross margin
- 85.22%
- Net margin
- -325.31%
- EBITDA margin
- -335.96%
- Revenue growth
- 698.96%
- Net income growth
- 63.97%
- Free cash flow growth
- -32.98%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -5.70%
- Current ratio
- 8.37x
- Net debt to EBITDA
- 0.05x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $62.90M
- Cost of revenue
- $9.30M
- Gross profit
- $53.60M
- EBITDA
- $-211.32M
- Net income
- $-204.63M
- Earnings per share
- $-0.60
- Research and development
- $115.11M
- Shares outstanding
- 341.54K
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $62.90M | $53.60M | $-204.63M | $-0.60 |
| 2024-12-31 | $7.87M | $795.00K | $-567.94M | $-2.11 |
| 2023-12-31 | - | - | $-75.80M | $-0.35 |
| 2022-12-31 | - | - | $-104.20M | $-0.48 |
| 2021-12-31 | - | - | $-86.85M | $-0.44 |
| 2020-12-31 | - | - | $-41.66M | $-0.43 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 85.22% | -325.31% | -66.93% | -107.08% |
| 2024-12-31 | 10.10% | -7213.76% | -122.46% | -135.62% |
| 2023-12-31 | - | - | -12.53% | -17.62% |
| 2022-12-31 | - | - | -15.91% | -21.45% |
| 2021-12-31 | - | - | -11.64% | -15.13% |
| 2020-12-31 | - | - | -19.37% | -22.99% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $164.09M | $47.21M |
| 2024-12-31 | $35.72M | - |
| 2023-12-31 | $42.65M | - |
| 2022-12-31 | $101.10M | - |
| 2021-12-31 | $132.42M | - |
| 2020-12-31 | $29.75M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-173.43M | $35.89M |
| 2024-12-31 | $-130.41M | $32.27M |
| 2023-12-31 | $-68.00M | $19.51M |
| 2022-12-31 | $-96.11M | $16.29M |
| 2021-12-31 | $-68.19M | $9.27M |
| 2020-12-31 | $-36.53M | $2.20M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-02
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | - |
| 2026-05-04 | - | - |
| 2026-03-02 | - | - |
| 2025-11-03 | - | - |
| 2025-08-07 | - | - |
| 2025-05-07 | - | - |
| 2025-03-06 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- nuvationbio.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades